Alaadin Vögeli1, Manuel Ottiger1, Marc A Meier1, Christian Steuer2, Luca Bernasconi2, Andreas Huber2, Mirjam Christ-Crain3, Christoph Henzen4, Claus Hoess5, Robert Thomann6, Werner Zimmerli7, Beat Mueller1, Philipp Schuetz8. 1. University Department of Internal Medicine, Kantonsspital Aarau, Tellstrasse, Aarau, CH-5001, Switzerland. 2. Department of Laboratory Medicine, Kantonsspital, Aarau, Switzerland. 3. Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland. 4. Department of Internal Medicine, Kantonsspital, Luzern, Switzerland. 5. Department of Internal Medicine, Kantonsspital, Münsterlingen, Switzerland. 6. Department of Internal Medicine, Bürgerspital, Solothurn, Switzerland. 7. University Department of Internal Medicine, Kantonsspital, Baselland, Switzerland. 8. University Department of Internal Medicine, Kantonsspital Aarau, Tellstrasse, Aarau, CH-5001, Switzerland. schuetzph@gmail.com.
Abstract
INTRODUCTION: In chronic obstructive pulmonary disease (COPD), there is an activation of the L-arginine nitric oxide pathway. Pulmonary obstruction causes to elevated nitric oxide (NO) levels, which lead to higher production of the NO-inhibiting metabolites asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). METHODS: We investigated the association of L-arginine, ADMA, and SDMA with clinical outcomes in a well-defined observational cohort of 150 patients with acute exacerbation of COPD. We measured L-arginine, ADMA, and SDMA by mass spectrometry in patients with pneumonic or non-pneumonic exacerbation of COPD included in a Swiss multicenter trial. We used Cox regression models to investigate the associations between blood marker levels and disease severity as well as all-cause mortality over a follow-up of 6.1 years. RESULTS: Six-year all-cause mortality was 54%. Admission levels of ADMA and SDMA (μmol L-1) were increased in 6-year non-survivors compared to survivors' median (0.60 vs. 0.46, p = 0.004; and 1.05 vs. 0.85, p = 0.012). In a multivariate Cox regression analysis, ADMA was associated with long-term mortality resulting in an age- and comorbidity-adjusted hazard ratio (HR) of 4.55 (95% confidence interval 1.02-20.43, p = 0.048). SDMA was only associated in univariate models and no association of L-arginine with outcome was found. CONCLUSION: ADMA was found to be an independent risk factor for long-term all-cause mortality in patients with acute exacerbation of COPD. Whether therapeutic modification of the L-arginine-nitric oxide pathway has the potential to improve outcome should be evaluated in future interventional trials.
INTRODUCTION: In chronic obstructive pulmonary disease (COPD), there is an activation of the L-argininenitric oxide pathway. Pulmonary obstruction causes to elevated nitric oxide (NO) levels, which lead to higher production of the NO-inhibiting metabolites asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). METHODS: We investigated the association of L-arginine, ADMA, and SDMA with clinical outcomes in a well-defined observational cohort of 150 patients with acute exacerbation of COPD. We measured L-arginine, ADMA, and SDMA by mass spectrometry in patients with pneumonic or non-pneumonic exacerbation of COPD included in a Swiss multicenter trial. We used Cox regression models to investigate the associations between blood marker levels and disease severity as well as all-cause mortality over a follow-up of 6.1 years. RESULTS: Six-year all-cause mortality was 54%. Admission levels of ADMA and SDMA (μmol L-1) were increased in 6-year non-survivors compared to survivors' median (0.60 vs. 0.46, p = 0.004; and 1.05 vs. 0.85, p = 0.012). In a multivariate Cox regression analysis, ADMA was associated with long-term mortality resulting in an age- and comorbidity-adjusted hazard ratio (HR) of 4.55 (95% confidence interval 1.02-20.43, p = 0.048). SDMA was only associated in univariate models and no association of L-arginine with outcome was found. CONCLUSION:ADMA was found to be an independent risk factor for long-term all-cause mortality in patients with acute exacerbation of COPD. Whether therapeutic modification of the L-arginine-nitric oxide pathway has the potential to improve outcome should be evaluated in future interventional trials.
Authors: Veronika Tanhäuserová; Josef Tomandl; Lukáš Pácal; Martin Klepárník; Denisa Malúšková; Vendula Bartáková; Katarína Kuricová; Jitka Rehořová; Soňa Stěpánková; Jan Svojanovský; Jindřich Olšovský; Jana Bělobrádková; Darja Krusová; Michal Jurajda; Jan Mužík; Tomáš Pavlík; Kateřina Kaňková Journal: Kidney Blood Press Res Date: 2012-11-11 Impact factor: 2.687
Authors: Jeremy A Scott; Michelle L North; Mahroukh Rafii; Hailu Huang; Paul Pencharz; Padmaja Subbarao; Jaques Belik; Hartmut Grasemann Journal: Am J Respir Crit Care Med Date: 2011-10-01 Impact factor: 21.405
Authors: Philipp Schuetz; Mirjam Christ-Crain; Marcel Wolbers; Ursula Schild; Robert Thomann; Claudine Falconnier; Isabelle Widmer; Stefanie Neidert; Claudine A Blum; Ronald Schönenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Müller Journal: BMC Health Serv Res Date: 2007-07-05 Impact factor: 2.655
Authors: Peter Neyer; Luca Bernasconi; Jens A Fuchs; Martina D Allenspach; Christian Steuer Journal: J Clin Lab Anal Date: 2019-10-08 Impact factor: 2.352